
Navigating the Digital Generation: Social Media & Mental Health
In today's podcast, we explore the connection between social media, mental health, and today's youth. We cover
On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.
https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/